Blazed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 3.00 Cr
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.46 M
- Revenue Growth %
- Profit Growth 32.38%
- Ebitda 46.47%
- Net Worth -50.32%
- Total Assets -14.99%
About Blazed Pharmaceuticals
Blazed Pharmaceuticals Private Limited (BPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 26 March 2019 (Five years and ten months 8 days old ). Its registered office is in Yelahanka, Bengaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company has closed loans amounting to ₹1.46 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Padakannaya Ibbani and Bommai Aditi serve as directors at the Company.
Company Details
-
Location
Yelahanka, Bengaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100KA2019PTC122732
-
Company No.
122732
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Mar 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Blazed Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padakannaya Ibbani
|
Director | 21-Sep-2023 | Current |
|
Bommai Aditi
|
Director | 21-Sep-2023 | Current |
Financial Performance of Blazed Pharmaceuticals.
Blazed Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 32.38% increase in profit. The company's net worth observed a substantial decline by a decrease of 50.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Blazed Pharmaceuticals?
In 2023, Blazed Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
K4u Apparels And Accessories Private LimitedPadakannaya Ibbani is a mutual person
Charges (Loans)
₹0
₹0.15 Cr
Charges Breakdown by Lending Institutions
- Canara Bank : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Feb 2023 | Canara Bank | ₹1.46 M | Satisfied |
How Many Employees Work at Blazed Pharmaceuticals?
Unlock and access historical data on people associated with Blazed Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Blazed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Blazed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
